Bone Properties in Hypoparathyroidism: Effects of PTH

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2013 by Columbia University.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
John P. Bilezikian, Columbia University Identifier:
First received: May 14, 2007
Last updated: July 26, 2013
Last verified: July 2013

Whereas much information is known about the properties of bone in primary hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The purpose of this research project is to test the hypothesis that the skeleton in hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and microarchitectural features. We will also test the hypothesis that the skeleton is dependent upon PTH for normal structure and function. Using non-invasive approaches as well as direct analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized. With each patient serving as his/her own control, we will determine how, to what extent, and in what ways the administration of PTH restores skeletal dynamics and structure to the hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography, geometry and size quantification, histomorphometry by standard and microCT methods, finite element analysis, biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH action on bone gained by our many years of studying PTH overexpression in primary hyperparathyroidism. This investigation may also provide insight into the means by which PTH helps to restore the skeleton when it is used to treat osteoporosis.

Condition Intervention Phase
Drug: PTH
Phase 2
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bone Properties in Hypoparathyroidism: Effects of PTH

Resource links provided by NLM:

Further study details as provided by Columbia University:

Primary Outcome Measures:
  • Improvement in calcium homeostasis, as evidenced by a reduction in requirements for calcium supplementation [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 43
Study Start Date: September 2005
Estimated Study Completion Date: November 2013
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: no intervention
participants receive open-label PTH1-84 in another study that they participate in. This study however does not provide or otherwise utilize an intervention or study arms of any kind, yet the story of this study would be incomplete without mentioning the use of PTH1-84 in the other study.
Drug: PTH
100mcg of PTH1-84 every other day, every day, or every three days
Other Names:
  • teriparatide
  • Preotact
  • PTH
  • PTH1-84
  • rhPTH
  • Natpara


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hypoparathyroidism

Exclusion Criteria:

  • Bisphosphonate use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00473265

United States, New York
Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
John P. Bilezikian
Principal Investigator: John P Bilezikian, MD Columbia University
  More Information

No publications provided

Responsible Party: John P. Bilezikian, Dorothy L. and Daniel H. Silberberg Professor of Medicine and Pharmacology, Columbia University Identifier: NCT00473265     History of Changes
Other Study ID Numbers: AAAA5457, R01DK069350
Study First Received: May 14, 2007
Last Updated: July 26, 2013
Health Authority: United States: Food and Drug Administration
United States: Federal Government

Additional relevant MeSH terms:
Endocrine System Diseases
Parathyroid Diseases processed this record on July 05, 2015